161 related articles for article (PubMed ID: 35466753)
1. Association between plasma somatic copy number variations and response to immunotherapy in patients with programmed death-ligand 1-negative non-small cell lung cancer.
Zhang X; Wang Y; Xiang J; Zhao P; Xun Y; Zhang S; Xu N
J Int Med Res; 2022 Apr; 50(4):3000605221093222. PubMed ID: 35466753
[TBL] [Abstract][Full Text] [Related]
2. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Frigola J; Navarro A; Carbonell C; Callejo A; Iranzo P; Cedrés S; Martinez-Marti A; Pardo N; Saoudi-Gonzalez N; Martinez D; Jimenez J; Sansano I; Mancuso FM; Nuciforo P; Montuenga LM; Sánchez-Cespedes M; Prat A; Vivancos A; Felip E; Amat R
Mol Oncol; 2021 Apr; 15(4):887-900. PubMed ID: 33342055
[TBL] [Abstract][Full Text] [Related]
3. Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC.
Hong TH; Bang YH; Joe CY; Hwang S; Lee B; Lee N; Park S; Jung HA; Sun JM; Ahn JS; Ahn MJ; Choi YL; Lee SH
J Thorac Oncol; 2023 Jul; 18(7):896-906. PubMed ID: 37028596
[TBL] [Abstract][Full Text] [Related]
4.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
[TBL] [Abstract][Full Text] [Related]
6. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
9. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
10. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50.
Gainor JF; Rizvi H; Jimenez Aguilar E; Skoulidis F; Yeap BY; Naidoo J; Khosrowjerdi S; Mooradian M; Lydon C; Illei P; Zhang J; Peterson R; Ricciuti B; Nishino M; Zhang J; Roth JA; Grishman J; Anderson D; Little BP; Carter BW; Arbour K; Sauter JL; Mino-Kenudson M; Heymach JV; Digumarthy S; Shaw AT; Awad MM; Hellmann MD
Ann Oncol; 2020 Mar; 31(3):404-411. PubMed ID: 32067682
[TBL] [Abstract][Full Text] [Related]
11. Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer.
Murugesan K; Jin DX; Comment LA; Fabrizio D; Hegde PS; Elvin JA; Alexander B; Levy MA; Frampton GM; Montesion M; Roychowdhury S; Kurzrock R; Ross JS; Albacker LA; Huang RSP
Oncologist; 2022 Sep; 27(9):732-739. PubMed ID: 35598202
[TBL] [Abstract][Full Text] [Related]
12. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
13. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
14. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
Shim JH; Kim HS; Cha H; Kim S; Kim TM; Anagnostou V; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Park WY; Lee SH
Ann Oncol; 2020 Jul; 31(7):902-911. PubMed ID: 32320754
[TBL] [Abstract][Full Text] [Related]
15. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
17. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
18. Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer.
Hisakane K; Seike M; Sugano T; Matsuda K; Kashiwada T; Nakamichi S; Matsumoto M; Miyanaga A; Noro R; Kubota K; Gemma A
Gene; 2023 Mar; 857():147177. PubMed ID: 36623674
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
[TBL] [Abstract][Full Text] [Related]
20. Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Ranganath H; Jain AL; Smith JR; Ryder J; Chaudry A; Miller E; Hare F; Valasareddy P; Seitz RS; Hout DR; Varga MG; Schweitzer BL; Nielsen TJ; Mullins J; Ross DT; Gandara DR; Vidal GA
BMC Cancer; 2022 Apr; 22(1):407. PubMed ID: 35421940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]